Evidence map›Paper›PMID 38770622›Full record

ArticleCancer medicine2024

Disparities in treatment patterns and mortality in prostate cancer: Interaction between Black race and end-stage kidney disease.

Nagaraju Sarabu, Weichuan Dong, Siran M Koroukian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nagaraju SarabuDivision of Nephrology, Department of Medicine, The Metrohealth System, Cleveland, Ohio, USA.ORCID 0000-0001-6084-8677
Weichuan DongPopulation and Quantitative Health Sciences, Population Cancer Analytics Shared Resource, and the Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-3981-658X
Siran M KoroukianPopulation and Quantitative Health Sciences, Population Cancer Analytics Shared Resource, and the Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-8106-9581

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
Multi-Level Interventions to Reduce Caries Disparities in Primary Care SettingsUH3DE025487 · NIDCR · CASE WESTERN RESERVE UNIVERSITY · PI NELSON, SUCHITRA S. · 2017 to 2021
$5.6M
Identifying Electronic Phenotypes associated with Patient Health Outcomes of Interhospital Transfer PatientsR15NR017792 · NINR · CASE WESTERN RESERVE UNIVERSITY · PI REIMER, ANDREW PAUL · 2018 to 2018
$477k
NCCDPHP CDC HHS NU58DP007160NCCDPHP CDC HHS U48 DP005030NCCDPHP CDC HHS U48 DP006404NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS P30 CA043703NIDCR NIH HHS UH3 DE025487NINR NIH HHS R15 NR017792University Hospital Cleveland
6 · The paper itself

Abstract

backgroundBlack men and men with end-stage kidney disease have lower rates of treatment and higher mortality for prostate cancer. We studied the interaction of end-stage kidney disease (ESKD) with Black race for treatment rates and mortality for men with prostate cancer. METHODS AND

resultsWe included 516 Black and 551 White men with ESKD before prostate cancer 22,299 Black men, and 141,821 White men without ESKD who were 40 years or older from the Surveillance, Epidemiology, and End-Results-Medicare data (2004-2016). All Black men with or without ESKD and White men with ESKD had higher prostate-specific antigen levels at diagnosis than White men without ESKD. Black men with ESKD had the lowest rates for treatment in both local and advanced stages of prostate cancer (age-adjusted risk ratio: 0.76, 95% Confidence Interval (CI): 0.71-0.82 for local stage and age-adjusted risk ratio: 0.82, 95% CI: 0.76-0.9 for advanced stages) compared to White men without ESKD. Compared to White men without ESKD, prostate cancer-specific mortality was higher in White men with ESKD for both local and advanced stages (age-adjusted hazard ratio: 1.8, 95% CI: 1.2-2.8 and HR: 1.6, 95% CI: 1.2-2.2) and it was higher for ESKD Black men only in advanced stage prostate cancer (age-adjusted hazard ratio: 2.4, 95% CI: 1.5-3.6).

conclusionOur findings suggest that having a comorbidity such as ESKD makes Black men more vulnerable to racial disparities in prostate cancer treatment and mortality.

Indexed as

Black or African AmericanHealthcare DisparitiesKidney Failure, ChronicProstatic NeoplasmsSEER ProgramWhite PeopleAgedAged, 80 and overHumansMaleMedicareMiddle AgedProstate-Specific AntigenUnited StatesProstate-Specific AntigenBlack raceend‐stage kidney diseasemortalityprostate cancerracial disparitytreatment

Identifiers

PMID38770622
PMCPMC11106677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.